vs

Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and NewtekOne, Inc. (NEWT). Click either name above to swap in a different company.

NewtekOne, Inc. is the larger business by last-quarter revenue ($73.3M vs $47.7M, roughly 1.5× IRONWOOD PHARMACEUTICALS INC). NewtekOne, Inc. runs the higher net margin — 111.8% vs -4.8%, a 116.6% gap on every dollar of revenue. On growth, NewtekOne, Inc. posted the faster year-over-year revenue change (-2.7% vs -47.3%). IRONWOOD PHARMACEUTICALS INC produced more free cash flow last quarter ($74.6M vs $-579.3M). Over the past eight quarters, NewtekOne, Inc.'s revenue compounded faster (12.2% CAGR vs -20.2%).

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.

NewTek, Inc., is a hardware and software company, based in San Antonio, Texas, that produced live and post-production video tools and visual imaging software for personal computers. The company was founded in 1985 in Topeka, Kansas, United States, by Tim Jenison and Paul Montgomery. On April 1, 2019, it was announced that NewTek would be acquired by Vizrt.

IRWD vs NEWT — Head-to-Head

Bigger by revenue
NEWT
NEWT
1.5× larger
NEWT
$73.3M
$47.7M
IRWD
Growing faster (revenue YoY)
NEWT
NEWT
+44.6% gap
NEWT
-2.7%
-47.3%
IRWD
Higher net margin
NEWT
NEWT
116.6% more per $
NEWT
111.8%
-4.8%
IRWD
More free cash flow
IRWD
IRWD
$653.9M more FCF
IRWD
$74.6M
$-579.3M
NEWT
Faster 2-yr revenue CAGR
NEWT
NEWT
Annualised
NEWT
12.2%
-20.2%
IRWD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IRWD
IRWD
NEWT
NEWT
Revenue
$47.7M
$73.3M
Net Profit
$-2.3M
$19.5M
Gross Margin
Operating Margin
14.3%
Net Margin
-4.8%
111.8%
Revenue YoY
-47.3%
-2.7%
Net Profit YoY
-200.9%
6.6%
EPS (diluted)
$0.01
$0.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRWD
IRWD
NEWT
NEWT
Q4 25
$47.7M
$73.3M
Q3 25
$122.1M
$74.9M
Q2 25
$85.2M
$70.2M
Q1 25
$41.1M
$66.3M
Q4 24
$90.5M
$75.4M
Q3 24
$91.6M
$62.8M
Q2 24
$94.4M
$61.1M
Q1 24
$74.9M
$58.3M
Net Profit
IRWD
IRWD
NEWT
NEWT
Q4 25
$-2.3M
$19.5M
Q3 25
$40.1M
$17.9M
Q2 25
$23.6M
$13.7M
Q1 25
$-37.4M
$9.4M
Q4 24
$2.3M
$18.3M
Q3 24
$3.6M
$11.9M
Q2 24
$-860.0K
$10.9M
Q1 24
$-4.2M
$9.7M
Operating Margin
IRWD
IRWD
NEWT
NEWT
Q4 25
14.3%
Q3 25
61.8%
Q2 25
53.2%
Q1 25
-70.7%
Q4 24
34.8%
Q3 24
28.0%
Q2 24
26.5%
Q1 24
14.7%
Net Margin
IRWD
IRWD
NEWT
NEWT
Q4 25
-4.8%
111.8%
Q3 25
32.8%
23.9%
Q2 25
27.7%
19.5%
Q1 25
-90.9%
14.1%
Q4 24
2.5%
24.3%
Q3 24
4.0%
19.0%
Q2 24
-0.9%
17.9%
Q1 24
-5.6%
16.6%
EPS (diluted)
IRWD
IRWD
NEWT
NEWT
Q4 25
$0.01
$0.64
Q3 25
$0.23
$0.67
Q2 25
$0.14
$0.52
Q1 25
$-0.23
$0.35
Q4 24
$0.03
$0.70
Q3 24
$0.02
$0.45
Q2 24
$-0.01
$0.43
Q1 24
$-0.03
$0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRWD
IRWD
NEWT
NEWT
Cash + ST InvestmentsLiquidity on hand
$215.5M
Total DebtLower is stronger
$819.9M
Stockholders' EquityBook value
$-261.8M
$397.6M
Total Assets
$396.9M
$2.7B
Debt / EquityLower = less leverage
2.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRWD
IRWD
NEWT
NEWT
Q4 25
$215.5M
Q3 25
$140.4M
Q2 25
$92.9M
Q1 25
$108.5M
Q4 24
$88.6M
Q3 24
$88.2M
Q2 24
$105.5M
Q1 24
$121.5M
Total Debt
IRWD
IRWD
NEWT
NEWT
Q4 25
$819.9M
Q3 25
$199.5M
$748.5M
Q2 25
$199.3M
$657.3M
Q1 25
$199.2M
$774.0M
Q4 24
$199.0M
$708.0M
Q3 24
$198.8M
$655.8M
Q2 24
$198.6M
$652.0M
Q1 24
$398.3M
$662.5M
Stockholders' Equity
IRWD
IRWD
NEWT
NEWT
Q4 25
$-261.8M
$397.6M
Q3 25
$-264.2M
$386.7M
Q2 25
$-308.2M
$312.2M
Q1 25
$-334.1M
$302.3M
Q4 24
$-301.3M
$296.3M
Q3 24
$-311.3M
$281.8M
Q2 24
$-321.7M
$274.0M
Q1 24
$-330.5M
$254.1M
Total Assets
IRWD
IRWD
NEWT
NEWT
Q4 25
$396.9M
$2.7B
Q3 25
$396.1M
$2.4B
Q2 25
$342.9M
$2.1B
Q1 25
$327.2M
$2.1B
Q4 24
$350.9M
$2.1B
Q3 24
$389.5M
$1.7B
Q2 24
$395.6M
$1.6B
Q1 24
$438.8M
$1.5B
Debt / Equity
IRWD
IRWD
NEWT
NEWT
Q4 25
2.06×
Q3 25
1.94×
Q2 25
2.11×
Q1 25
2.56×
Q4 24
2.39×
Q3 24
2.33×
Q2 24
2.38×
Q1 24
2.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRWD
IRWD
NEWT
NEWT
Operating Cash FlowLast quarter
$74.6M
$-579.2M
Free Cash FlowOCF − Capex
$74.6M
$-579.3M
FCF MarginFCF / Revenue
156.3%
-790.0%
Capex IntensityCapex / Revenue
0.0%
0.1%
Cash ConversionOCF / Net Profit
-29.64×
TTM Free Cash FlowTrailing 4 quarters
$127.0M
$-1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRWD
IRWD
NEWT
NEWT
Q4 25
$74.6M
$-579.2M
Q3 25
$47.6M
$-167.3M
Q2 25
$-15.1M
$-199.8M
Q1 25
$20.0M
$-60.7M
Q4 24
$15.2M
$-153.0M
Q3 24
$9.9M
$-25.7M
Q2 24
$33.5M
$2.9M
Q1 24
$45.0M
$-38.7M
Free Cash Flow
IRWD
IRWD
NEWT
NEWT
Q4 25
$74.6M
$-579.3M
Q3 25
$47.6M
$-167.3M
Q2 25
$-15.1M
$-199.9M
Q1 25
$19.9M
$-60.7M
Q4 24
$-153.5M
Q3 24
$9.9M
$-25.9M
Q2 24
$33.4M
$2.9M
Q1 24
$44.9M
$-38.7M
FCF Margin
IRWD
IRWD
NEWT
NEWT
Q4 25
156.3%
-790.0%
Q3 25
39.0%
-223.3%
Q2 25
-17.7%
-284.7%
Q1 25
48.4%
-91.6%
Q4 24
-203.6%
Q3 24
10.8%
-41.2%
Q2 24
35.4%
4.7%
Q1 24
60.0%
-66.5%
Capex Intensity
IRWD
IRWD
NEWT
NEWT
Q4 25
0.0%
0.1%
Q3 25
0.0%
0.0%
Q2 25
0.0%
0.1%
Q1 25
0.1%
0.1%
Q4 24
0.0%
0.6%
Q3 24
0.0%
0.4%
Q2 24
0.1%
0.1%
Q1 24
0.1%
0.1%
Cash Conversion
IRWD
IRWD
NEWT
NEWT
Q4 25
-29.64×
Q3 25
1.19×
-9.35×
Q2 25
-0.64×
-14.58×
Q1 25
-6.48×
Q4 24
6.74×
-8.35×
Q3 24
2.71×
-2.15×
Q2 24
0.27×
Q1 24
-4.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons